Screener
Bruker BRKR Bsi Calid — Research And Development Expense
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Bruker in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Bruker’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:24 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-335226
| Line item | Three Months Ended June 30, 2026 / BSI Bio Spin | Three Months Ended June 30, 2026 / BSI CALID | Three Months Ended June 30, 2026 / BSI NANO | Three Months Ended June 30, 2026 / BEST | Three Months Ended June 30, 2026 / Total | Three Months Ended June 30, 2025 / BSI Bio Spin | Three Months Ended June 30, 2025 / BSI CALID | Three Months Ended June 30, 2025 / BSI NANO | Three Months Ended June 30, 2025 / BEST | Three Months Ended June 30, 2025 / Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Segment expenses: | ||||||||||
| Cost of revenue | $94.1 | $126.1 | $123.7 | $59.8 | $403.7 | $108.1 | $125.6 | $125.6 | $52.3 | $411.6 |
| Selling, general and administrative | 38.4 | 79.3 | 68.6 | 5.8 | 192.1 | 40.9 | 76.9 | 72.7 | 5.7 | 196.2 |
| Research and development | 21.5 | 32.6 | 39.2 | 1.0 | 94.3 | 23.2 | 30.0 | 44.4 | 1.1 | 98.7 |
| Segment operating income | $41.7 | $72.3 | $29.8 | $7.6 | $151.4 | $23.1 | $53.3 | $9.4 | $7.2 | $93.0 |
| Reconciliation of Total operating income: | ||||||||||
| Corporate, elimination and other (a) | $32.8 | $21.1 | ||||||||
| Adjustments and reconciling items (b) | 183.9 | 60.0 |
ITEM 1. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FAQ
- What is Bruker's bsi calid — research and development expense?
- Bruker (BRKR) reported bsi calid — research and development expense of $32.6M in Q2 2026.
- How has Bruker's bsi calid — research and development expense changed year-over-year?
- Bruker's bsi calid — research and development expense increased by 8.7% year-over-year, from $30M to $32.6M.
- What is the long-term trend for Bruker's bsi calid — research and development expense?
- Over 3 years (2022 to 2025), Bruker's bsi calid — research and development expense has grown at a 16.9% compound annual growth rate (CAGR), from $75M to $119.7M.
- What does bsi calid — research and development expense mean?
- Expenditures dedicated to the discovery, design, and improvement of scientific instruments and diagnostic technologies. This investment is critical for maintaining long-term competitive advantage and innovation within the life sciences sector.
Ask your AI about Bruker's bsi calid — research and development expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude